Latest Updates view all

Tenant News: COTI Identifies Phase 1Oral Formulation Candidates for COTI-2 http://stillerc... [Read More]
Tenant News: COTI Initiates Preclinical Trials of AML Drug Candidates: http://www.stillerc... [Read More]
RT @venturelondon Cash, profile, renewed vision! Some benefits of winning VLBC--Tonya Cons... [Read More]
Find The Stiller Centre on Facebook

Stiller Centre Tenant News

Submitted by admin on Mon, 03/22/2010 - 23:00

Tenant News: Oral COTI-2 is effective against triple negative human breast cancer
 
London, Ontario (March 30, 2010): Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT)
announced positive test results today from a series of animal experiments carried out at a prominent
Canadian cancer research facility with COTI‐2 as a single agent against an aggressive strain of triple
negative human breast cancer (TNBC); MDA‐MB‐231‐luc.
The significance of this development is that TNBC is a difficult‐to‐treat cancer subtype that does not
have an approved standard‐of‐care and does not respond to current hormone‐based and targeted
therapies. TNBC is a very aggressive cancer, with higher rates of metastases and poorer survival rates
than other breast cancer subtypes.

For the complete press release and more information on Critical Outcome Technologies Inc., go to: COTI